Burkitt lymphoma of the uterus in a human T lymphotropic virus type-1 carrier.

Abstract

A 71-year-old Japanese woman who was seropositive for T-lymphotropic virus type-1 (HTLV-1) developed primary Burkitt lymphoma of the uterus. CT showed marked enlargement of the uterine body. Chromosomal abnormalities were detected in biopsied cells, and most showed the t (8; 14) (q24; q32) translocation. Fluorescence in situ hybridization (FISH) with a dual-color stain for IgH/C-MYC fusion showed 99% positively. Biopsies from abdominal operation were diagnosed as Burkitt lymphoma. Treatment was started with intensive chemotherapy according to a protocol for Burkitt lymphoma and mature-B cell leukemia. Two regimens were done with four courses with rituximab. Treatment response was fast, with a documented and lasting first complete remission on CT and laboratory markers after the 4 cycle treatment.

• Authors: Shosaku Nomura, Kazuyoshi Ishii, Yoshiko Shimamoto, Yoshihisa Yamamoto, Eiji Kadota
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 45 Issue 4 Pg. 215-7 ( 2006) ISSN: 1349-7235 [Electronic] Japan
• PMID: 16543692 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents
• Rituximab

Topics

• Aged
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Burkitt Lymphoma (drug therapy, genetics, pathology, virology)
• Endemic Diseases
• Female
• Humans
• In Situ Hybridization, Fluorescence
• Japan (epidemiology)
• Leukemia-Lymphoma, Adult T-Cell (drug therapy, epidemiology, genetics, pathology)
• Remission Induction
• Rituximab
• Seroepidemiologic Studies
• Translocation, Genetic
• Uterine Neoplasms (drug therapy, genetics, pathology, virology)